Loading
A phase 1 trial of DT-7012 run by Assistance Publique - Hôpitaux de Paris, not yet recruiting.
A Phase 1, Multicenter, Open-label, Prospective, First-in-human Dose-escalation Clinical Trial of Domain Therapeutics' Anti-CCR8 Monoclonal Antibody (DT-7012) in Patients With Relapsed or Refractory Cutaneous T-cell Lymphomas (CTCL) is a phase 1 interventional study registered as NCT07213882 by Assistance Publique - Hôpitaux de Paris, with 30 participants planned, started 2026-01-01. Conditions recorded: Cutaneous T Cell Lymphoma (CTCL), Mycosis Fungoides and Sezary Syndrome. Interventions recorded: DT-7012.
Shares DT-7012, Kainova Therapeutics and the tag pipeline.
Shares DT-7012, Kainova Therapeutics and the tag pipeline.
Shares Mycosis fungoides, Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome), Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Mycosis fungoides, Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome) and the tag pipeline.
Shares Kainova Therapeutics and the tag pipeline.
Shares Mycosis fungoides, Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome) and the tag pipeline.
Shares Mycosis fungoides, Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome) and the tag pipeline.
Shares Kainova Therapeutics and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/